BioStock: Phase II results indicate durability of response for Alligator’s CD40 agonist
Alligator Bioscience has presented a second round of interim results from a phase II trial with mitazalimab in pancreatic cancer patients. The follow-up evaluation on the first 23 patients shows an objective response rate of 57 per cent – up from 52 per cent at the first evaluation reported in January. The evaluation on the full set of 57 patients reveals an objective response rate of 44 per cent – also susceptible to an increase as the study progresses. More data points indicate that mitazalimab provides a durable response in combination with standard of care chemotherapy. To give us an in-depth analysis, BioStock turned to Alligator’s CMO Sumeet Ambarkhane.
Read the interview with Sumeet Ambarkhane at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/